Noroviruses (NVs) called “Norwalk-like viruses” are a group of single-stranded positive sense RNA viruses and members of the
family Caliciviridae. NVs are transmitted from human-to-human and are one of the most highly infectious viruses known. In the
community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms usually resolving
after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge.
In the US, which does not yet have active national surveillance, norovirus infections may account for 235,000 clinic visits, 91,000
emergency room visits and 23.000 hospitalizations among children <5 years of age. There is also evidence that norovirus epidemics
are growing in magnitude, severity and in the elderly population, may even be causing fatalities. NV outbreaks are also a well known
issue for military installations and commercial cruise ship liners.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of Norovirus vaccines across major Western and emerging markets to 2030. The model contains value ($ m) and volume
(mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are
included based upon the level of populations targeted by a potential vaccine.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 17.5%.
Please review the TERMS and CONDITIONS of purchase.
